pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
Pierre Fabre Medicament clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
Pierre Fabre Medicament projects
4 ClinicalTrials.gov programs sponsored by Pierre Fabre Medicament.
Pierre Fabre Medicament has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
EBVALLO
Pierre Fabre Medicament
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
1 trial -
ER004
Pierre Fabre Medicament
X-linked hypohidrotic ectodermal dysplasia (XLHED)
1 trial -
F60087CI101
Pierre Fabre Medicament
locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
1 trial -
PFL721CI101
Pierre Fabre Medicament
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does Pierre Fabre Medicament have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.